Obesity
Conference Coverage
Don’t be afraid of weight gain with hyperthyroid treatment
A large study shows highest weight gain risk is with thyroidectomy, and radioiodine therapy is linked to better survival.
Guidelines
New AGA guidelines advise use of antiobesity medications for weight management
Though lifestyle interventions are the first-line treatment for overweight and obesity, use of specific pharmacological agents should be...
From the Journals
It’s about location: PCOS symptoms differ depending where you live
Women with PCOS in California were more likely to have hyperandrogenemia than were those in Alabama, but age and BMI weren’t factors, nor was race...
From the Journals
Weight loss history affects success in obesity management
A retrospective study yields a surprising finding about the weight-loss success of older women with experience in dieting.
Conference Coverage
Tirzepatide’s benefits expand: Lean mass up, serum lipids down
New results from the SURMOUNT-1 trial of tirzepatide in people with obesity show further positive effects.
Commentary
Playing the fat shame game in medicine: It needs to stop
One study has suggested that over 40% of adults in the United States have suffered from weight stigma, and physicians and coworkers are listed as...
From the Journals
Bariatric surgery prompts visceral fat reduction, cardiac changes
Weight loss after bariatric surgery was tied to favorable cardiac effects associated with reduction in visceral fat.
From the Journals
Eating earlier offers health benefits, studies say
“You have this internal biological clock that makes you better at doing different things at different times of the day.”
From the Journals
Food insecurity a growing problem for many with CVD
The number of Americans with cardiovascular disease who have limited or uncertain access to food has more than doubled over the last 20 years.
News
Bariatric surgery may up risk for epilepsy
“We now know that the microbiome is associated with epilepsy” and that changes occur in the gut microbiome after bariatric surgery.
Conference Coverage
Ezetimibe-statin combo lowers liver fat in open-label trial
A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks’ treatment with ezetimibe and rosuvastatin comparing baseline with end of...